What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after ...

Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Vertex (NASDAQ:VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved ...

Investors didn't seem to be in a forgiving mood with the company's quarterly and annual guidance. That morning, Vertex revealed that its total revenue was slightly over $192 million in the third ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Vertex ( ($VERX) ) has shared an update. On November 14, 2025, Vertex, Inc. entered into the First Amendment to its Amended and Restated Credit ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

The tax software specialist delivered double-digit growth on the top line in its latest quarter. Adjusted net income also rose, albeit not as steeply. That morning, Vertex revealed that its total ...